ArticleScience (New York, N.Y.)2012
Comment on "Impaired respiratory and body temperature control upon acute serotonergic neuron inhibition".
Article in Science (New York, N.Y.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 11 citations in OpenAlex.
- Chemogenetic activation of Gq signaling modulates dendritic development of cortical neurons in a time- and layer-specific manner.Frontiers in cellular neuroscience · 2025Article
- Chemogenetic Silencing of Differentiating Cortical Neurons Impairs Dendritic and Axonal Growth.Frontiers in cellular neuroscience · 2022Article
- Circuit directionality for motivation: Lateral accumbens-pallidum, but not pallidum-accumbens, connections regulate motivational attraction to reward cues.Neurobiology of learning and memory · 2019Article
- Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice.Scientific reports · 2019Article
- Gram scale preparation of clozapineMethodsX · 2018Article
- Optogenetic approaches for dissecting neuromodulation and GPCR signaling in neural circuits.Current opinion in pharmacology · 2017Review
- Gi-DREADD Expression in Peripheral Nerves Produces Ligand-Dependent Analgesia, as well as Ligand-Independent Functional Changes in Sensory Neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2016Article
- The Use of DREADDs to Deconstruct Behavior.Frontiers in genetics · 2016Review
- The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.ACS chemical neuroscience · 2015Article
- Article
- Article
- Control of cutaneous blood flow by central nervous system.Temperature (Austin, Tex.)Review
Corrections and comments
- Comment on
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ray et al. (Reports, 29 July 2011, p. 637) assume that clozapine-N4-oxide (CNO) represents a "biologically inert synthetic ligand" that selectively activates the M4 muscarinic receptor-based DREADD (designer receptor exclusively activated by a designer drug). In contrast, due to the redox cycling of CNO with clozapine and to their cell membrane permeability, CNO is biologically active and its conversion products are capable of undermining DREADD effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.